Bispecific Antibodies for PD-1 and VEGF: Impact and Market Dynamics for IO Landscape

xml encoding="UTF-8"

xml encoding="utf-8" ?

xml encoding="utf-8" ?

About this podcast:

This podcast, recorded at the 2025 Immuno-Oncology 360º (IO360º) Summit, explores the clinical and market implications of emerging data on bispecific antibodies targeting PD-1 and VEGF and their potential to disrupt existing immunotherapy paradigms.

More specifically:

x-tinymce/html

• Assessing the potential of this therapeutic approach to challenge established treatments like pembrolizumab by targeting both PD-1 and VEGF
• Insights into how these developments could influence industry trends and investor sentiment
• Forward-looking forecasts on market share and commercial positioning for PD-1/PD-L1 and VEGF-targeting therapies

For more information, go to IO360summit.com.

Speakers

Roy Baynes, MD, PhD

EVP & CMO

Eikon Therapeutics

Asthika Goonewardene, MBA

Managing Director, Senior Biotech Analyst

Truist Securities

This content was created by The Conference Forum staff. The Fierce editorial team did not contribute to this work.